A Phase 2 interventional study of VERVE-102 and Placebo in Atherosclerosis, Cardiovascular Disease and Hypercholesterolemia, sponsored by Verve Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Verve Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
1,517 studies on the registry are indexed under Atherosclerosis; 224 are open to participants now.
This study's planned enrollment of 175 is above the median of 100 across 879 interventional studies indexed under Atherosclerosis.
Browse Atherosclerosis studies →Verve Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
First submitted after Verve Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive a single dose of VERVE-102 intravenously (IV)
Drug: VERVE-102
Participants will receive a single dose of VERVE-102 IV
Drug: VERVE-102
Participants will receive a single dose of VERVE-102 IV
Drug: VERVE-102
Participants will receive a single dose of placebo IV
Drug: Placebo
Administered IV
Also known as: LY4636581
Administered IV
Percent Change from Baseline in LDL-C
Time frame: Baseline, Day 90
Percent Change from Baseline in LDL-C
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline Total Cholesterol
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
Time frame: Baseline to End of Study (up to Day 365)
Percent Change from Baseline in Apolipoprotein B
Time frame: Baseline to End of Study (up to Day 365)
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.